Your browser doesn't support javascript.
loading
Factors correlated with repeated aspirin dosing during aspirin desensitization.
Schuler, Charles F; Baldwin, James L; Baptist, Alan P.
Afiliación
  • Schuler CF; Division of Allergy and Clinical Immunology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: schulerchase@gmail.com.
  • Baldwin JL; Division of Allergy and Clinical Immunology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan.
  • Baptist AP; Division of Allergy and Clinical Immunology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan.
Ann Allergy Asthma Immunol ; 121(1): 111-116.e1, 2018 07.
Article en En | MEDLINE | ID: mdl-29653235
ABSTRACT

BACKGROUND:

Aspirin desensitization is an appropriate procedure for many patients with aspirin-exacerbated respiratory disease (AERD). Patients can require aspirin re-dosing, which prolongs the desensitization process. The frequency of this is not widely reported, nor is it known which patients will require multiple re-dosing.

OBJECTIVE:

To determine the frequency of and factors associated with repeat aspirin re-dosing during desensitization.

METHODS:

Charts of aspirin desensitization procedures from 2011 to 2016 at the University of Michigan Allergy/Immunology Clinic were reviewed. Reactions with provoking doses and number of dose repetitions were characterized. Previous AERD history, medical history, medications, and baseline spirometry were also recorded. Bivariate correlation and multivariate logistic regression were used to analyze associations between patient characteristics and need for repeated dosing of aspirin.

RESULTS:

A total of 84 positive-reacting patients during desensitization were identified. Of these patients, 33% required 2 or more aspirin dose repetitions during desensitization. Requiring 2 or more repeat doses during desensitization was associated with male gender (odds ratio = 6.194, P = .008), forced expiratory volume in 1 second (FEV1) decrease during desensitization (odds ratio = 1.075 per percent point drop, P = .021), and initial aspirin provoking dose during desensitization of 81 mg or lower (odds ratio = 11.111, P = .003). No association was found with pre-desensitization medications, asthma severity, AERD duration, or number/character of reported previous aspirin reactions.

CONCLUSION:

During aspirin desensitization for AERD, approximately one third of our patients require multiple repeat doses. Risk factors for multiple repeated doses include male gender, drop in FEV1, and lower aspirin provoking doses during desensitization. This information can help inform which patients may require multiple re-dosing for desensitization.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aspirina / Desensibilización Inmunológica / Asma Inducida por Aspirina Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Allergy Asthma Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2018 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aspirina / Desensibilización Inmunológica / Asma Inducida por Aspirina Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Allergy Asthma Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2018 Tipo del documento: Article